Bypassing pre-existing antibodies extends the applicability of AAV-based retinal therapies

Mol Ther. 2023 Dec 6;31(12):3363. doi: 10.1016/j.ymthe.2023.11.005. Epub 2023 Nov 23.
No abstract available